| Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH‐dependent solubility the Achilles heel of targeted therapy? NR Budha, A Frymoyer, GS Smelick, JY Jin, MR Yago, MJ Dresser, ... Clinical Pharmacology & Therapeutics 92 (2), 203-213, 2012 | 386 | 2012 |
| Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy A Rotte, JY Jin, V Lemaire Annals of Oncology 29 (1), 71-83, 2018 | 376 | 2018 |
| Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma M Stroh, H Winter, M Marchand, L Claret, S Eppler, J Ruppel, O Abidoye, ... Clinical Pharmacology & Therapeutics 102 (2), 305-312, 2017 | 146 | 2017 |
| Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding RA Graham, BL Lum, S Cheeti, JY Jin, K Jorga, DD Von Hoff, CM Rudin, ... Clinical Cancer Research 17 (8), 2512-2520, 2011 | 141 | 2011 |
| Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies Y Chen, JY Jin, S Mukadam, V Malhi, JR Kenny Biopharmaceutics & drug disposition 33 (2), 85-98, 2012 | 135 | 2012 |
| Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays JY Jin, RR Almon, DC DuBois, WJ Jusko The journal of pharmacology and experimental therapeutics 307 (1), 93-109, 2003 | 118 | 2003 |
| Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors PM LoRusso, A Jimeno, G Dy, A Adjei, J Berlin, L Leichman, JA Low, ... Clinical Cancer Research 17 (17), 5774-5782, 2011 | 113 | 2011 |
| A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer S Cheeti, NR Budha, S Rajan, MJ Dresser, JY Jin Biopharmaceutics & drug disposition 34 (3), 141-154, 2013 | 107 | 2013 |
| Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical … D Lu, S Girish, Y Gao, B Wang, JH Yi, E Guardino, M Samant, M Cobleigh, ... Cancer chemotherapy and pharmacology 74, 399-410, 2014 | 88 | 2014 |
| Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting KM Morrissey, M Marchand, H Patel, R Zhang, B Wu, H Phyllis Chan, ... Cancer Chemotherapy and Pharmacology 84, 1257-1267, 2019 | 83 | 2019 |
| Progress and opportunities to advance clinical cancer therapeutics using tumor dynamic models R Bruno, D Bottino, DP De Alwis, AT Fojo, J Guedj, C Liu, KR Swanson, ... Clinical Cancer Research 26 (8), 1787-1795, 2020 | 77 | 2020 |
| A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non–small cell lung cancer based on early tumor kinetics L Claret, JY Jin, C Ferté, H Winter, S Girish, M Stroh, P He, M Ballinger, ... Clinical Cancer Research 24 (14), 3292-3298, 2018 | 77 | 2018 |
| Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2 … AL Quartino, C Hillenbach, J Li, H Li, RD Wada, J Visich, C Li, ... Cancer Chemotherapy and Pharmacology 77, 77-88, 2016 | 77 | 2016 |
| Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology K Yoshida, N Budha, JY Jin Clinical Pharmacology & Therapeutics 101 (5), 597-602, 2017 | 68 | 2017 |
| Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle RR Almon, DC DuBois, JY Jin, WJ Jusko Journal of endocrinology 184 (1), 219-232, 2005 | 61 | 2005 |
| Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver JY Jin, DC DuBois, RR Almon, WJ Jusko The Journal of pharmacology and experimental therapeutics 309 (1), 328-339, 2004 | 61 | 2004 |
| Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modelling J Lu, B Bender, JY Jin, Y Guan Nature machine intelligence 3 (8), 696-704, 2021 | 58 | 2021 |
| The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria MR Yago, A Frymoyer, LZ Benet, GS Smelick, LA Frassetto, X Ding, ... The AAPS journal 16, 1358-1365, 2014 | 50 | 2014 |
| Challenges and opportunities in dose finding in oncology and immuno‐oncology Y Ji, JY Jin, DM Hyman, G Kim, A Suri Clinical and translational science 11 (4), 345-351, 2018 | 49 | 2018 |
| Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series RR Almon, DC Dubois, JY Jin, WJ Jusko The AAPS journal 7, E156-E194, 2005 | 48 | 2005 |